id: NEW:glycemic_control_hba1c_to_NEW:type_1_diabetes_clinical_outcomes
name: Glycemic Control (HbA1c) → Type 1 Diabetes Clinical Outcomes
from_node:
  node_id: NEW:glycemic_control_hba1c
  node_name: Glycemic Control (HbA1c)
to_node:
  node_id: NEW:type_1_diabetes_clinical_outcomes
  node_name: Type 1 Diabetes Clinical Outcomes
direction: positive
category: biological
mechanism_pathway:
- 'Step 1: Glycosylated hemoglobin (HbA1c) reflects average blood glucose levels over
  2-3 months, serving as a key marker of glycemic control in Type 1 Diabetes'
- 'Step 2: Interventions targeting glycemic control (e.g., telemedicine with individualized
  assessments, audit with feedback, and skill building) lead to measurable reductions
  in HbA1c levels'
- 'Step 3: Improved glycemic control (lower HbA1c) is associated with reduced risk
  of microvascular and macrovascular complications characteristic of Type 1 Diabetes
  clinical outcomes'
- 'Step 4: Sustained glycemic control over longer durations (>6 months) produces larger
  clinical benefits, particularly in patients with higher baseline HbA1c (≥9%)'
evidence:
  quality_rating: A
  n_studies: 38
  primary_citation: 'Shaun Wen Huey Lee et al. 2017. Telemedicine for the Management
    of Glycemic Control and Clinical Outcomes of Type 1 Diabetes Mellitus: A Systematic
    Review and Meta-Analysis of Randomized Controlled Studies. Frontiers in Pharmacology.'
  supporting_citations: []
description: Meta-analysis of 38 randomized controlled studies demonstrates that interventions
  improving glycemic control (measured by HbA1c) are associated with Type 1 Diabetes
  clinical outcomes. A mean reduction of 0.18% in HbA1c was observed, with greater
  effects in longer interventions and patients with poorer baseline control. However,
  no significant benefits were observed for secondary outcomes including blood pressure,
  lipids, weight, quality of life, or adverse events.
last_updated: '2025-12-02'
extraction_method: consolidated_batch_v3
quantitative_effects:
  effect_size:
    value: -0.18
    type: mean_difference
    ci_lower: null
    ci_upper: null
  p_value: null
  sample_size: null
moderators:
- name: intervention_duration
  direction: strengthens
  strength: moderate
  description: Studies with longer duration (>6 months) were associated with larger
    effects on glycemic control
- name: baseline_HbA1c
  direction: strengthens
  strength: moderate
  description: Patients with higher baseline HbA1c (≥9%) showed larger improvements
    in glycemic control
- name: intervention_components
  direction: strengthens
  strength: moderate
  description: Interventions involving individualized assessments, audit with feedback,
    and skill building were more effective
